FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2986471650> ?p ?o ?g. }

• W2986471650 endingPage "3172" @default.
• W2986471650 startingPage "3172" @default.
• W2986471650 abstract "Background: [18F]-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) positivity after first line treatment with autologous stem cell transplantation (ASCT), is strongly correlated with reduced progression free survival and overall survival (Moreau et al., JCO, 2017). However, FDG PET/CT positive patients who obtain FDG PET/CT negativity after treatment can have comparable outcomes to patients who were FDG PET/CT negative at baseline (Davies et al., Haematologica 2018). Aiming for FDG PET/CT negativity may therefore be an important goal in myeloma treatment. The use of FDG PET/CT positivity as an indication for consolidation therapy after ASCT has not been studied before. Methods: This is an ongoing, multicenter phase II study. Patients with multiple myeloma who have received standard first line treatment including ASCT and achieved very good partial response (VGPR) or better, are eligible for the study and examined by FDG PET/CT. Patients who are FDG PET/CT positive defined by the Italian Myeloma criteria for PET USe (IMPETUS) (Nanni C et al., EJNMMI 2016 and 2018) are included in the treatment phase of the study and are assessed for minimal residual disease (MRD) by Euroflow (sensitivity: 10-5) before treatment. The treatment consists of four 28-day cycles of KRd (carfilzomib 36 mg/m2 day 1,2,8,19,15 and 16 (except 20 mg/m2 day 1 and 2 first cycle), lenalidomide 25 mg day 1-21 all cycles and dexamethasone 40 mg day 1,8,15 and 22 all cycles). After four cycles, FDG PET/CT and Euroflow for MRD are repeated for response evaluation. Both patients with FDG PET/CT negativity and patients with FDG PET/CT positivity at baseline are followed for progression free survival (PFS) and overall survival (OS). Results: As of 1st of July 2019, 43 patients have been screened in the study. Sixteen patients (37%) had a positive FDG PET/CT result. Eight of 13 (62%) patients with a FDG PET/CT positive result were MRD negative. Eight patients have completed four cycles of KRD consolidation; two patients were converted into FDG PET/CT negativity; one of the two remained MRD positive, the other remained MRD negative. Three patients had reduced FDG uptake but were still considered FDG PET/CT positive; one of these converted from MRD positive to negative. One had stable disease and two had progression on FDG PET/CT whereof one converted from MRD negative to positive. Conclusion: A significant proportion (37%) of patients treated with standard first line treatment including ASCT with very good partial response or better was considered FDG PET/CT positive. Sixty-two percent of these patients were MRD negative by Euroflow, confirming the complementary features of these two methods. Treatment with four cycles of KRd improved disease status based on FDG PET/CT in 5 of 8 patients (62,5%) and converted 2 out of 8 patients to FDG PET/CT negativity. One patient was converted from MRD positivity to MRD negativity. This study is ongoing and will enroll 50 FDG PET/CT positive patients. Before the ASH 2019 meeting, we plan to screen approximately fifteen additional patients with FDG PET/CT and about five more patients will have completed KRd consolidation therapy. Table Disclosures Nørgaard: Bayer, Astrazeneca: Honoraria. Abildgaard:Janssen: Research Funding; Celgene: Research Funding; Takeda: Research Funding; Amgen: Research Funding. Revheim:South-Eastern Norway Regional Healt Authority: Research Funding. Schjesvold:Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; MSD: Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; SkyliteDX: Honoraria; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding." @default.
• W2986471650 created "2019-11-22" @default.
• W2986471650 creator A5000125623 @default.
• W2986471650 creator A5009288737 @default.
• W2986471650 creator A5013808699 @default.
• W2986471650 creator A5028832113 @default.
• W2986471650 creator A5060699933 @default.
• W2986471650 creator A5078740906 @default.
• W2986471650 date "2019-11-13" @default.
• W2986471650 modified "2023-09-26" @default.
• W2986471650 title "Krd Consolidation in Myeloma Patients with a Positive PET-CT after Standard First Line Treatment: A Phase II Study (CONPET)" @default.
• W2986471650 doi "https://doi.org/10.1182/blood-2019-125523" @default.
• W2986471650 hasPublicationYear "2019" @default.
• W2986471650 type Work @default.
• W2986471650 sameAs 2986471650 @default.
• W2986471650 citedByCount "2" @default.
• W2986471650 countsByYear W29864716502020 @default.
• W2986471650 crossrefType "journal-article" @default.
• W2986471650 hasAuthorship W2986471650A5000125623 @default.
• W2986471650 hasAuthorship W2986471650A5009288737 @default.
• W2986471650 hasAuthorship W2986471650A5013808699 @default.
• W2986471650 hasAuthorship W2986471650A5028832113 @default.
• W2986471650 hasAuthorship W2986471650A5060699933 @default.
• W2986471650 hasAuthorship W2986471650A5078740906 @default.
• W2986471650 hasConcept C126322002 @default.
• W2986471650 hasConcept C127077266 @default.
• W2986471650 hasConcept C2775842073 @default.
• W2986471650 hasConcept C2776063141 @default.
• W2986471650 hasConcept C2776364478 @default.
• W2986471650 hasConcept C2779050716 @default.
• W2986471650 hasConcept C2780108899 @default.
• W2986471650 hasConcept C2780401358 @default.
• W2986471650 hasConcept C2989005 @default.
• W2986471650 hasConcept C71924100 @default.
• W2986471650 hasConceptScore W2986471650C126322002 @default.
• W2986471650 hasConceptScore W2986471650C127077266 @default.
• W2986471650 hasConceptScore W2986471650C2775842073 @default.
• W2986471650 hasConceptScore W2986471650C2776063141 @default.
• W2986471650 hasConceptScore W2986471650C2776364478 @default.
• W2986471650 hasConceptScore W2986471650C2779050716 @default.
• W2986471650 hasConceptScore W2986471650C2780108899 @default.
• W2986471650 hasConceptScore W2986471650C2780401358 @default.
• W2986471650 hasConceptScore W2986471650C2989005 @default.
• W2986471650 hasConceptScore W2986471650C71924100 @default.
• W2986471650 hasIssue "Supplement_1" @default.
• W2986471650 hasLocation W29864716501 @default.
• W2986471650 hasOpenAccess W2986471650 @default.
• W2986471650 hasPrimaryLocation W29864716501 @default.
• W2986471650 hasRelatedWork W1985864219 @default.
• W2986471650 hasRelatedWork W2340942222 @default.
• W2986471650 hasRelatedWork W2546436011 @default.
• W2986471650 hasRelatedWork W2738602720 @default.
• W2986471650 hasRelatedWork W2750658188 @default.
• W2986471650 hasRelatedWork W2892083382 @default.
• W2986471650 hasRelatedWork W3005849948 @default.
• W2986471650 hasRelatedWork W3029900969 @default.
• W2986471650 hasRelatedWork W3212617436 @default.
• W2986471650 hasRelatedWork W4293087867 @default.
• W2986471650 hasVolume "134" @default.
• W2986471650 isParatext "false" @default.
• W2986471650 isRetracted "false" @default.
• W2986471650 magId "2986471650" @default.
• W2986471650 workType "article" @default.